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Soluble guanylate cyclase (sGC) is a key enzyme of the nitric oxide–cyclic guanosine 30,50-
monophosphate (NO–cGMP) signaling pathway, and its pharmacological stimulation has
been shown to prevent the development of emphysema and pulmonary vascular remodeling
in animal models of chronic obstructive pulmonary disease (COPD). The aim of this study
was to evaluate the effects of sGC stimulation on oxidative stress in the plasma of guinea
pigs chronically exposed to cigarette smoke (CS).
Methods and results
Guinea pigs were exposed to CS or sham for three months, and received either the sGC
stimulator BAY 41–2272 or vehicle. Body weight was measured weekly; and markers of oxi-
dative stress in plasma, and airspace size and inflammatory cell infiltrate in lung tissue were
analyzed at the end of the study. Compared to sham-exposed guinea pigs, CS-exposed ani-
mals gained less body weight and showed higher plasma levels of nitrated tyrosine residues
(3-NT), 4-hydroxynonenal (4-HNE), and 8-hydroxydeoxyguanosine (8-OHdG). Treatment
with the sGC stimulator led to a body weight gain in the CS-exposed guinea pigs similar to
non-exposed and attenuated the increase in 3-NT and 4-HNE. Plasma levels of 3-NT corre-
lated with the severity of inflammatory cell infiltrate in the lung.
Conclusion
Stimulation of sGC prevents oxidative stress induced by CS exposure and is associated
with an attenuated inflammatory response in the lung.







Citation: Paul T, Salazar-Degracia A, Peinado VI,
Tura-Ceide O, Blanco I, Barreiro E, et al. (2018)
Soluble guanylate cyclase stimulation reduces
oxidative stress in experimental Chronic
Obstructive Pulmonary Disease. PLoS ONE 13(1):
e0190628. https://doi.org/10.1371/journal.
pone.0190628
Editor: Yunchao Su, Augusta University, UNITED
STATES
Received: April 21, 2017
Accepted: December 18, 2017
Published: January 5, 2018
Copyright: © 2018 Paul et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: The study has been funded by grants
from the Instituto de Salud Carlos III (PS09/0536,
PI14/00713 and PI16/01147), an unrestricted
educational grant from Bayer AG, the Spanish
Society of Respiratory Medicine (SEPAR) (24/2015
and /2016) and Catalan Foundation of
Pulmonology (FUCAP) (FUCAP 2016).
Introduction
Chronic obstructive pulmonary disease (COPD), which is a consequence of cigarette smoking,
is one of the most common causes of chronic morbidity and death in the world [1]. It not only
affects the respiratory system but also increases the risk of systemic manifestations and serious
comorbidities, such as cardiovascular disease, skeletal muscle dysfunction and cachexia [2,3].
These extrapulmonary manifestations further impair quality of life in COPD patients and sub-
stantially worsens their prognosis, regardless of the changes occurring in the lung [4–7].
Cigarette smoke (CS) contains harmful substances that produce an inflammatory response
and excessive oxidative stress in the lung [8,9]. The spill-over of inflammatory mediators from
the lung to the circulation has been postulated as the potential mechanism of the systemic
manifestations of COPD [10]. As a source of reactive oxygen species (ROS), this may provoke
the oxidation of various biomolecules that generate further reactive molecules when interact-
ing with toxic chemicals in the CS [11]. For instance, levels of ROS-modified proteins, lipid
peroxidation, and oxidatively damaged DNA were shown to be elevated in the blood plasma of
smokers and patients with COPD [12–14]. These are biomarkers of oxidative damage to skele-
tal muscle proteins and organs in smokers [15].
Nitric oxide (NO) signaling is essential for many physiological processes and has been
proven to be impaired by oxidative stress [16,17]. Under normal conditions, NO activates the
key enzyme soluble guanylate cyclase (sGC), which converts guanosine triphosphate (GTP) to
cyclic guanosine monophosphate (cGMP). As a second messenger, cGMP controls vascular
tone and suppresses smooth muscle proliferation, platelet aggregation, and many other pro-
cesses [18]. In smokers and patients with COPD, reduced sGC expression, together with com-
promised function because of oxidation, have been demonstrated in bronchial and alveolar
epithelial cells and in airway smooth muscle cells [19,20]. Pharmacologic stimulation of sGC is
able to prevent the development of pulmonary hypertension and emphysema in rodent models
of COPD [21]. These preventive effects were attributed, at least in part, to the ability of cGMP
to reduce inflammatory cell recruitment to the lung and its ability to neutralize damage from
oxidative stress by preventing ROS-induced apoptosis and upregulating production of the
antioxidant superoxide dismutase (SOD) 1 [21]. Whether the effects of cGMP are limited to
the lung or are extended to extrapulmonary organs remains unsettled.
Given its known pulmonary antioxidant properties, it is conceivable that sGC stimulators
could have effects on systemic oxidative stress [21]. The present study aimed to evaluate extra-
pulmonary effects of sGC stimulation in guinea pigs chronically exposed to CS, a well-estab-
lished experimental model of COPD [22], preventing systemic oxidative stress. We investigated
the effects of the sGC stimulator BAY 41–2272 [23] on the formation of ROS and nitrogen spe-
cies, as measured by identification of well-validated indirect markers of oxidative stress in
guinea pig plasma after 3 months of CS exposure. We then studied the relationship between
these biomarkers and structural and inflammatory changes in the lung.
Material and methods
Exposure to CS
Thirty-one male Dunkin-Hartley guinea pigs (start weight: 350g-400g, age: 4–5 weeks) were
purchased from Harlan Laboratories, Inc. and provided with standard guinea pig chow and
water supplemented with ascorbic acid (Bayer Hispania, Sant Joan Despı́, Spain) ad libitum in
non-metabolic cages. Animals were housed at controlled conditions (temperature: 20–22˚C,
fixed 12h day/night cycles). After 2 weeks of adaptation, animals were randomly divided into
four groups: (1) a sham-exposed control group that received a control vehicle (Polyethylene
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glycol 400, 5ml/Kg); Fluka Analytical, Sigma-Aldrich, Steinheim, Germany) (n = 7); (2) a
sham-exposed treatment group that received the sGC stimulator BAY 41–2272 (provided by
Bayer AG, Leverkusen, Germany) (n = 8); (3) a CS-exposed control group that received the
vehicle only (n = 7); and (4) a CS-exposed treatment group that received BAY 41–2272 (n = 9).
CS exposure was conducted as previously described [21,25,27], with guinea pigs exposed to the
smoke of 6 cigarettes (3R4F, Kentucky University Research, Lexington, KY, USA) per day, 5
days a week, for 3 months. After CS exposure, animals received daily doses of either freshly
prepared BAY 41–2272 in suspension at a dose of 3 mg/kg by oral gavage or an equivalent
amount of the vehicle. Conditions of the guinea pigs were controlled daily before the manipu-
lation and their body weights were measured once per week. Body mass index (BMI) was cal-
culated by dividing the bodyweight by the square of the body length. As the animals tolerated
the procedure without complications, application of human endpoints for animals was not
necessary. When sacrificed, animals were anesthesized with urethane (2g/kg i.p.; Sigma-
Aldrich, Steinheim, Germany) and euthanized by exsanguination. All procedures were
approved by the ethics committee for animal experimentation of the University of Barcelona
(registry: 2009/5026). An initial set of assessments in these animals have been previously pub-
lished [22,24–26]
Histological analysis of the lung to validate the experimental model
Methodology for the histologic assessments in the lung have previously been described [21].
Emphysema was assessed by histological hematoxylin staining, measuring the mean linear
intercept (MLI) according to standard procedures in 20 randomly selected microscopic fields
[21,27]. Inflammatory cells were counted on histological sections stained with hematoxylin
and eosin or periodic acid-Schiff, as previously described [21,26]. Intraseptal neutrophils were
identified by their segmented nuclei. Cell quantity was related to the septal area, which was
measured using Image-Pro Plus software (Media Cybernetics, Inc.). Alveolar macrophages
were identified based on their morphology and glycogen content [21]. Results on the preven-
tive effects of BAY 41–2272 on emphysema development and inflammatory cell infiltrate in
the lung after CS-exposure have been previously reported [21]. In the present study we analyze
the correlation between oxidative stress and such histological assessments.
Oxidative stress markers in blood
Plasma samples were produced by centrifuging EDTA-blood at 2500 RPM for 5 minutes at
4˚C. Plasma levels of 3-nitrotyrosine (3-NT), 4-hydroxynonenal (4-HNE), and 8-hydroxy-
deoxyguanosine (8-OHdG) were assessed by enzyme-linked immunosorbent assays (ELISA;
OxiSelect™ Nitrotyrosine ELISA kit, OxiSelect™ HNE Adduct Competitive ELISA kit and Oxi-
Select™ oxidative DNA Damage ELISA kit, Cell Biolabs, Inc. San Diego, CA, USA) following
the manufacturer’s instructions and previously reported methodologies [28,29]. Briefly, 50 μL
of each sample were added to designated wells and incubated at room temperature for 10 min-
utes. These samples were then incubated with an additional 50 μL of diluted primary antibody
at room temperature for one hour. Thereafter, samples were washed with a wash buffer and
incubated with 100 μL of diluted secondary antibody-enzyme conjugate for an additional
hour. Finally, the samples were washed several times with a wash buffer and incubated with
100 μL of the substrate solutions for 30 minutes in the dark. The enzyme reaction was stopped
by adding 100 μL of a stop solution. A standard curve was always generated for each assay run.
Absorbancies were read in a microplate reader (infinite M200, TECAN, Switzerland) at 450
nm using a reference filter of 655 nm.
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Plasma biochemical measurements
Total cholesterol, total proteins and triglycerides serum levels were measured using standard
enzymatic procedures by the Laboratory of Biochemistry of the Hospital Clı́nic of Barcelona.
Western blotting
Frozen lung tissue was homogenized (T 10 basic ULTRA-TURRAX1, IKA.) and lysed in a
buffer containing 50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 150
mM NaCl, 100 mM sodium fluoride (NaF), 10 mM tetrasodium pyrophosphate (Na4P2O7), 5
mM ethylenediaminetetraacetic acid (EDTA), 0.5% Triton-X, 2 μg/mL leupeptin, 100 μg/mL
phenylmethylsulfonyl fluoride (PMSF), 2 μg/mL aprotinin, and 10 μg/mL pepstatin A. After-
wards, samples were centrifuged at 1000g for 30 min and protein levels were determined in the
supernatant using the Bradford method (Protein Assay Dye Reagent Concentrate, Bio-rad).
30μg of total protein were loaded on gels, separated by SDS-PAGE and transferred to polyviny-
lidene difluoride (PVDF) membranes. Membranes were blocked in 1% BSA and incubated
with the primary antibodies overnight (BAX (p19) sc-526, 1:2000 in PBS-Tween; Santa Cruz
or GAPDH (FL-355) sc-25778, dilution 1:2000, Santa Cruz). Proteins of interest were indi-
rectly detected using horseradish peroxidase (HRP)–conjugated secondary antibodies (Jackson
ImmunoResearch Inc, West Grove, PA, USA) and visualized with a chemiluminescence kit
(Thermo scientific, Rockford, IL, USA). Membranes were scanned using the Molecular Imager
Chemidoc XRS System (Bio-Rad Laboratories, Hercules, CA, USA) and Quantity One version
4.6.5- software (Bio-Rad Laboratories). All membranes with samples of the different experi-
mental groups were analyzed in the same picture with identical exposure times. Optical densi-
ties (OD) of the bands were quantified using the Image Lab- software version 2.0.1 (Bio-Rad
Laboratories). ODs of the protein of interest were normalized by the ODs of the loading con-
trol GAPDH.
Immunohistochemistry
Paraffin-embedded tissue sections were rehydrated and incubated for 40 min in 1mM EDTA
(with 0.05% tween, pH 8) at 95˚C. Then, the endogenous peroxidase was blocked with 6%
H2O2 (in H2O) for 15min, before slides were incubated for 30 min with the primary antibody
(BAX (p19) sc-526, Santa Cruz, 1/20 in PBS) at room temperature. After that, specific proteins
were detected with a secondary antibody against primary antibody for 30 min at room temper-
ature and visualized with the Dako REALTM EnVisionTM Detection System (Peroxidase/DAB
+ Rabbit/Mouse, code k5007, DAKO, Glostrup, Denmark). Nuclei were counterstained with
hematoxylin for 2 minutes. After dehydrating and mounting tissue sections in DPX, light
microscopy pictures were taken with an Olympus BX 61 microscope (Olympus Corporation,
Tokyo, Japan) which was equipped with an image-digitizing camera (Olympus DP 71, Olym-
pus Corporation).
Statistical analysis
Because the study design was two-factorial, each factor with two levels [Factor 1 (CS): CS-
exposure vs. non-exposed animals and, Factor 2 (treatment): BAY 41–2272 vs. vehicle only],
all experiments were analyzed by two-way analysis of variance (ANOVA) with CS exposure
and BAY 41–2272 treatment considered independently when comparing the results between
experimental groups. P-values for the independent factors are represented in Tables 1 and 2.
To fulfill the assumptions of the two-way ANOVA, data were transformed by forming the
square root or natural logarithm to achieve normal distribution of the datasets, if necessary. If
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a significant interaction of the two factors was found in the 2-way ANOVA, pairwise multiple
comparisons between the experimental groups were performed using Holm–Šidák post-hoc
tests and are represented in the text and in the graphs by p-values. To evaluate the potential
relationship between study variables, Spearman rank analysis was carried out. In all cases, p-
values below 0.05 were considered statistically significant. Missing data of individual animals
are related to technical problems and are indicated in the n-numbers below the graphs.
Results
Lung morphometry, body weight, and nutritional status
Guinea pigs exposed to CS developed pulmonary emphysema, as shown by increased MLI
(p<0.001 for the comparison of CS+vehicle with sham+vehicle) (Table 1, S1 Fig), and inflam-
matory cell infiltrate in lung tissue, with evidence of increased numbers of neutrophils in alve-
olar septa and macrophages in alveolar spaces, as previously reported [21] (Table 1, S2 Fig).
Furthermore, CS-exposed animals showed less weight gain compared with the corresponding
control group in week 13 (Table 1, Fig 1A); similarly, the BMI at week 13 was significantly
decreased in CS-exposed guinea pigs compared with sham-exposed animals (Table 1, Fig 1B).
Treatment with BAY 41–2272 prevented the increase of MLI (p = 0.002 for the comparison
of CS+vehicle and CS+BAY 41–2272) (Table 1, S1 Fig), and cell infiltrate by neutrophils and
macrophages was attenuated (Table 1, S2 Fig). Moreover, the two-way ANOVA revealed a sig-
nificant interaction between CS exposure and treatment with BAY 41–2272 regarding the
extents of emphysema and neutrophilic cell infiltrate (Table 1).
In addition, treatment with BAY 41–2272 almost normalized weight gain among CS-
exposed guinea pigs. Body weight at week 13 in the CS+BAY 41–2272 group was similar to the
unexposed group, and significantly higher in animals which received treatment (Table 1, Fig
1A). BMI at week 13 was significantly higher in CS-exposed guinea pigs that received BAY 41–
2272 when compared to CS-exposed animals that received vehicle (Table 1, Fig 1B).
Table 1. Changes in emphysema extent, lung inflammation, plasma oxidative stress, apoptosis and bodyweight associated with BAY 41–2272
treatment in guinea pigs chronically exposed to CS.






















58 ± 4 59 ± 6 74 ± 6 62 ± 8 p<0.001 p = 0.05 p = 0.008
Neutrophils (x10-7cells/
μm2)
1.61 ± 0.7 1.88 ± 0.52 4.17 ± 1.66 1.73 ± 0.59 p = 0.004 p = 0.02 p = 0.001
Macrophages (cells/
field)
0.81 ± 0.08 0.57 ± 0.2 1.33 ± 0.24 0.94 ± 0.15 p<0.001 p<0.001 p = 0.27
NT (nM) 8.7 ± 5.4 8.3 ± 4.8 21.7 ± 15.3 7.0 ± 4.9 p = 0.16 p = 0.02 p = 0.03
4-HNE (μg/ml) 1.9 ± 1.0 2.6 ± 1.4 6.7 ± 4.5 2.4 ± 1.6 p = 0.06 p = 0.19 p = 0.029
8-OHdG (ng/ml) 2.2 ± 0.4 2.6 ± 0.4 4.3 ± 2.4 3.3 ± 1.1 p = 0.006 p = 0.51 p = 0.19
BMI (kg/m2) 9.41 ± 0.53 9.89 ± 0.54 8.42 ± 0.51 9.03 ± 0.58 p<0.001 p = 0.009 p = 0.737
Bodyweight week 13 (g) 918,29 ± 57.37 976.88 ± 75.09 802.00 ± 57.37 873.11 ± 85.36 p<0.001 p = 0.021 p = 0.815
BAX/GAPDH ratio (OD) 0.12 ± 0.04 0.13 ± 0.03 0.32 ± 0.08 0.2 ± 0.06 p<0.001 p = 0.015 p = 0.003
CS = cigarette smoke, 3-NT = 3-nitrotyrosine, 4-HNE = 4-hydroxynonenal, 8-OHdG = 8-hydroxydeoxyguanosine, BMI = body mass index,
GAPDH = Glyceraldehyde 3-phosphate dehydrogenase, OD = optical densitiy. Values are expressed as mean ± SD in the different experimental groups.
Statistical differences were analyzed by 2-way ANOVA. Effects of CS exposure, BAY 41–2272 treatment, and their interaction, respectively, are
represented at the right of the table.
https://doi.org/10.1371/journal.pone.0190628.t001
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To further examine the impact of treatment with BAY 41–2272 on the nutritional status, we
analyzed serum protein, triglyceride and cholesterol levels. While triglycerides and cholesterol
levels did not differ from unexposed animals in the groups receiving BAY 41–2272, protein
levels were significantly higher guinea pigs treated with BAY 41–2272 (Table 2, S3 Fig).
Markers of oxidative stress in the plasma
Compared with sham-exposed animals, CS-exposed guinea pigs had significantly higher
plasma levels of 3-NT (p = 0.02), 4-HNE (p = 0.008), and 8-OHdG (Table 1, Fig 2). Treatment
with BAY 41–2272 prevented the increase of both 3-NT (p = 0.002) and 4-HNE (p = 0.02) as
compared with non treated CS-exposed animals. Furthermore, the levels of both molecules
did not differ from those in sham-exposed animals, and the interaction between CS exposure
and BAY 41–2272 treatment was statistically significant in the two-way ANOVA (Fig 2A and
2B, Table 1). Regarding 8-OHdG levels, a slight decrease was observed in CS exposed animals
after treatment with BAY 41–2272 but did not reach statistical significance (Table 1, Fig 2C).
Associations between plasma levels of oxidative stress markers and
inflammatory cell infiltrates in the lung
Plasma levels of 3-NT were significantly associated with the number of inflammatory cells
in the lungs (intraseptal neutrophils, R = 0.501; p = 0.007) throughout all study groups.
Table 2. Changes in nutritional status associated with BAY 41–2272 treatment in guinea pigs chronically exposed to CS.













Effect of CS Effect of BAY 41–
2272
Interaction between CS & BAY 41–
2272
Protein (g/L) 41 ± 5 45 ± 2 43 ± 4 46 ± 4 0.37 0.03 0.91
Triglyceride (mg/
dL)
185 ± 80 157 ± 31 159 ± 90 187 ± 105 0.69 0.97 0.49
Cholesterol (mg/
dL)
42 ± 18 42 ± 7 44 ± 18 43 ± 13 0.79 0.91 0.82
Representation of the mean ± SD in the different experimental groups. Statistical differences were analyzed by 2-way ANOVA. Effects of CS exposure, BAY
41–2272 treatment, and their interaction, respectively, are represented at the right of the table.
https://doi.org/10.1371/journal.pone.0190628.t002
* Sham + BAY 41-2272
Sham + Vehicle
CS + BAY 41-2272
CS + Vehicle
A)                                                                             B)
n=7              n=9                n=7              n=8
Fig 1. Body weight evolution in the different experimental groups (A). Statistical differences were analyzed by 2-way ANOVA and are shown in
Table 1. (B) Body mass index at week 13. All data are represented as mean ± SD.
https://doi.org/10.1371/journal.pone.0190628.g001
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Moreover, a correlation trend of 3-NT levels with lung macrophages was observed (R = 0.35;
p = 0.056) (Fig 3). Plasma levels of 8-OHdG and 4-HNE did not correlate significantly with
either the number of neutrophils or macrophages in the lungs (data not shown).
Impact of BAY 41–2272 on the regulation of apoptosis in lung tissue
Protein levels of the pro-apoptotic regulator BAX were significantly increased in animals
exposed to CS (p<0.001) when compared to controls (Fig 4A and Table 1). Treatment with
the sGC-stimulator BAY 41–2272 reduced BAX protein expression as analyzed by western
blot (p<0.001 for CS+Vehicle vs. CS+BAY 41–2272) (Fig 4A and 4B). Likewise, representative
immunohistochemically stained lung tissue sections showed lower levels of BAX in CS-
exposed animals which were treated with the sGC-stimulator when compared to CS-exposed
guinea pigs which did not receive the treatment (Fig 4C).
Discussion
Through the analysis of blood biomarkers, this study shows that the sGC stimulator BAY 41–2272
administered to guinea pigs chronically exposed to CS can prevent oxidative stress in the plasma.
A)                                                  B)                                                C)
n=7             n=8             n=7             n=8 n=7             n=8              n=6             n=8 n=7             n=8              n=7            n=9
Fig 2. Effects of soluble guanylate cyclase (sGC) stimulation on plasma markers of oxidative stress. Guinea pigs were exposed to either cigarette
smoke (CS) or sham for 3 months, and received either the sGC stimulator (BAY 41–2272) or vehicle only. (A) Presence of nitrated tyrosine residues (3-NT),
(B) 4-hydroxynonenal, and (C) 8-hydroxydeoxyguanosine were quantified by enzyme-linked immunosorbent assay (mean ± SD). Statistical differences were
analyzed by 2-way ANOVA. Pairwise multiple comparisons between the individual groups were performed using the Holm–Šidák method.
https://doi.org/10.1371/journal.pone.0190628.g002
A) B) Ɣ CS + Vehicle
○ CS + BAY 41-2272
Sham + Vehicle
Sham + BAY 41-2272
Fig 3. Correlation analysis of inflammatory cell infiltrate in the lungs (counted on histological sections) and plasma levels of oxidative stress
markers. Spearman rank correlation was used to evaluate the relationship between (A) intraseptal neutrophils (cells ×10−7/μm2) R = 0.501, p = 0.007 and (B)
macrophages (cells/field) R: 0.35, p = 0.056 and 3-NT. Assessment was by enzyme-linked immunosorbent assay.
https://doi.org/10.1371/journal.pone.0190628.g003
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In a previous publication we showed beneficial effects of sGC stimulation on emphysema
development, which could be partially explained by the ability of this class of drugs to inhibit
the induction of apoptosis, to increase antioxidant enzymes, and to stimulate mediators of vas-
cular and tissue integrity. Moreover, an attenuation of inflammation by BAY 41–2272 was dis-
cussed to contribute to the prevention of emphysema development [21]. Consistent with these
results in the present study we observed a significant relationship between the plasma levels of
oxidatively damaged proteins (3-NT) and inflammatory cells in the lung. However, besides the
abnormal inflammatory response present in the lungs, COPD is associated with systemic
inflammation that includes augmentation of pro-inflammatory cytokines, the activation of
inflammatory cells, and the development of oxidative stress in the circulation [30]. Our data
indicate that in this experimental model, treatment with sGC stimulators is able to correct
both pulmonary damage and systemic oxidant/antioxidant imbalances.
In guinea pigs, chronic CS exposure has previously been shown to induce transient, but
repetitive, systemic oxidative damage that has been considered responsible for impaired
metabolism and a reduced capacity of CS-exposed animals to gain body weight [31]. To find
evidence in support of this concept, we analyzed oxidative stress biomarkers (e.g., 3-NT,
4-HNE, and 8-OHdG) in plasma samples, and demonstrated that plasma oxidative damage
Fig 4. Effects of soluble guanylate cyclase stimulation on the regulation of apoptosis. Guinea pigs were exposed to either cigarette smoke (CS) or
sham for 3 months, and received either the sGC stimulator (BAY 41–2272) or vehicle only. (A) Protein expression of BAX was measured by western blot (A
and B) and immunohistochemistry (C). Statistical differences in western blotting results were analyzed by 2-way ANOVA. Pairwise multiple comparisons
between the individual groups were performed using the Holm–Šidák method.
https://doi.org/10.1371/journal.pone.0190628.g004
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was significantly increased by 3 months of CS exposure. By mediating a number of down-
stream mechanisms and compromising normal cell function, these molecules contribute to
the progression of the pulmonary and systemic features of COPD [32,33].
In line with our results, a trend has been shown for levels of TNF-α to increase in the circu-
lation and for plasma lipid peroxidation to increase acutely in guinea pigs after 6 months of CS
exposure [31]. Treatment with BAY 41–2272 attenuated the effects of CS exposure on plasma
levels of NT and 4-HNE in the present study. In pulmonary arterial hypertension, the NO–
cGMP axis has been shown to be involved in modulating the inflammatory and redox status,
with evidence that clinical improvement after sildenafil treatment was, at least in part, attribut-
able to a reduction of plasma 4-HNE levels [34]. In alveolar epithelial and endothelial cells,
sGC stimulation inhibits ROS-induced apoptosis and enhances SOD1 expression (an ROS
scavenger) [21]. The reduction in ROS damage and increase in antioxidant defense might
explain the plasma effects of the sGC stimulator in this study. Moreover, excessive oxidative
stress contributes to impaired NO-signaling, because high concentrations of 4-HNE have been
shown to cause eNOS-uncoupling, resulting in reduced NO bioavailability [35]. Accordingly,
stimulation of sGC by BAY 41–2272 may help preserve the physiological functions of the NO
pathway under conditions of oxidative stress.
Whether systemic inflammation and oxidative stress in COPD are consequences of pulmo-
nary impairment or they represent independent features remain a matter of debate [36–38]. A
proposed hypothesis for the origin of systemic features is the so called spill-over of local inflam-
matory events in the lungs to the circulation [10,39]. In support of this hypothesis, we found a
positive correlation between plasma 3-NT levels and neutrophilic granulocytes, with a trend
toward a positive correlation with macrophages in the lung. In addition, there is evidence that
neutrophils, circulating monocytes and macrophages of patients with COPD function abnor-
mally, being capable of producing more ROS and inflammatory mediators than those of
healthy individuals [40–42]. Through increased peroxynitrite production, for instance, this
may give rise to the observed protein modifications in the CS-exposed animals in the present
study.
It is well known that chronic hypoxemia may cause systemic inflammation, and that this
may add to the effects of lung inflammation associated with COPD [43]. In fact, it has been
observed that the degree of hypoxemia correlates with plasma inflammatory markers [44].
Hence, the ability of sGC stimulation to prevent both emphysema and inflammatory infiltra-
tion in the lungs could produce synergistic effects, resulting in fewer products of ROS damage
in plasma. Supporting previous explanations regarding protective effects of sCG stimulators
on apoptosis [21], we also found a decrease in the pro-apoptotic BAX protein in CS-exposed
animals treated with the drug. A negative regulation of apoptosis upon sGC-stimulator treat-
ment might additionally explain the favourable effects of this substance class on emphysema
development. Consistent with these findings, we also observed that both body weight gain and
BMI were reduced in the CS-exposed animals compared with the non-exposed controls. This
hints at a systemically impaired equilibrium in CS exposed animals. In the same animals, we
observed that intervention with BAY 41–2272 compensated for weight and BMI issues seen in
CS-exposed animals. Blood protein levels were elevated during treatment with BAY 41–2272
as well, allowing for the assumption that stimulation of sGC signaling exerts additional effects
to those already described for the lung [21]. Interestingly, similar effects on body weight gain
have been observed in guinea pigs chronically exposed to CS and treated with sildenafil [27]
further supporting the role of cGMP in body weight gain.
Our experiments have limitations. Notably, we used a preventive treatment design, so the
effects of sGC stimulation in a therapeutic setting, after the manifestation of COPD symptoms,
cannot be extrapolated based on our results. This will need to be addressed in future studies
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with a therapeutic design. In addition, further evaluation of plasma inflammation would have
been useful to help place our results concerning ROS damage in context. Currently, though,
there are few commercial antibodies against guinea pig proteins, and with several different
antibodies we could not detect inflammatory markers in the plasma of our subjects. Further-
more, we used a relatively low dose (3 mg/kg) of BAY 41–2272. We cannot rule out that a
higher dose might have possibly revealed stronger effects, particularly on 8-OHdG formation.
It is also likely that a greater number of animals would have increased the statistical power.
Even though we previously found beneficial effects of the drug on emphysema development
and lung inflammation, an improvement of lung function (measured by wholebody plethys-
mography) was not observed [21]. Similarly, even though the evaluated markers reflect oxida-
tive stress conditions reliably, our results cannot be translated directly into functional
limitations in the animals. For that reason, measuring exercise capacity would have been use-
ful, but would have added considerable complexity to our study design.
In conclusion, the present study shows that the sGC stimulator BAY 41–2272 can prevent
oxidative stress in the plasma in a validated guinea pig model of COPD. Whether these antiox-
idant properties result from diminished inflammation in the lung after sGC treatment or
whether they denote a direct extrapulmonary effect needs to be addressed in future investiga-
tions. Our results would imply that targeting oxidative stress in COPD might not only be bene-
ficial for treating pulmonary symptoms but also for preventing or improving its systemic
manifestations.
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S2 Fig. Recruitment of neutrophils (A) and macrophages (C) to the lung tissue. Data are
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phils (HE-staining, (B)) and macrophages (PAS-staining, (D)) and corresponding magnified
image details of the original pictures (frames). For statistics see Table 1 in the main manu-
script.
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S3 Fig. Changes in nutritional status associated with BAY 41–2272 treatment in guinea
pigs chronically exposed to CS. Dot plot of individual values for plasma protein, triglycerides




We thank Cristina Bonjoch for their expert technical assistance. The authors also thank
Michael Maudsley for English revision on the manuscript. This work was developed at the
Centre de Recerca Biomèdica Cellex, Barcelona, Spain.
Author Contributions
Conceptualization: Victor I. Peinado, Esther Barreiro, Joan A. Barberà.
Soluble guanylate cyclase and oxidative stress
PLOS ONE | https://doi.org/10.1371/journal.pone.0190628 January 5, 2018 10 / 13
Formal analysis: Tanja Paul, Anna Salazar-Degracia, Victor I. Peinado, Olga Tura-Ceide, Isa-
bel Blanco.
Funding acquisition: Victor I. Peinado, Esther Barreiro, Joan A. Barberà.
Methodology: Tanja Paul, Anna Salazar-Degracia, Victor I. Peinado, Esther Barreiro.
Project administration: Victor I. Peinado.
Supervision: Victor I. Peinado, Esther Barreiro, Joan A. Barberà.
Validation: Tanja Paul, Victor I. Peinado.
Writing – original draft: Tanja Paul, Victor I. Peinado.
Writing – review & editing: Victor I. Peinado, Olga Tura-Ceide, Isabel Blanco, Esther Bar-
reiro, Joan A. Barberà.
References
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